Form 4: ResMed CEO Michael Farrell's RSU Vesting and Tax Withholding

ResMed's Chairman and CEO, Michael J. Farrell, reported the vesting of 13,551 performance-based restricted stock units and the subsequent disposition of 7,297 shares for tax withholding.

Summary

• Michael J. Farrell, Chairman and CEO of ResMed Inc., reported changes in his beneficial ownership.
• On November 20, 2025, 13,551 shares of ResMed Common Stock were acquired due to the vesting of performance-based restricted stock units (RSUs) granted on November 16, 2022.
• The vesting occurred because the compensation and leadership development committee certified that the performance metrics were met.
• Concurrently, 7,297 shares were disposed of to the issuer for tax withholding purposes related to the RSU vesting.
• Following these transactions, Michael J. Farrell directly beneficially owns 466,223 shares of ResMed Common Stock.
• An additional 2,090 shares are indirectly beneficially owned through the Lisette and Michael Farrell Family Trust.

Sentiment

Score: 7

Explanation: The filing indicates successful achievement of performance metrics for executive compensation, which is a positive signal regarding past company performance. The transactions themselves are routine for executive equity compensation.

Positives

• The vesting of 13,551 performance-based restricted stock units indicates that the company's performance metrics, set in 2022, were successfully met.
• This demonstrates management's alignment with shareholder interests through performance-based compensation.

Negatives

• The disposition of 7,297 shares for tax withholding reduces the direct beneficial ownership of the CEO, although this is a standard practice for RSU vesting.

Industry Context

This filing is a routine disclosure of executive stock transactions, common across all publicly traded companies. The vesting of performance-based RSUs is a standard mechanism for executive compensation, aligning management incentives with long-term company performance in the medical device and healthcare technology sector.

Related Party Transactions

• Michael J. Farrell indirectly beneficially owns 2,090 shares through the Lisette and Michael Farrell Family Trust.

Stakeholder Impact

• Shareholders: The successful vesting of performance-based RSUs suggests that the company met its strategic goals, which could be viewed positively by shareholders.
• Employees: The compensation structure for the CEO, tied to performance, reflects a common practice in executive compensation, potentially influencing broader employee incentive programs.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting of performance-based restricted stock units and subsequent tax withholding. While the successful vesting indicates the achievement of prior performance targets, it does not provide new material information that would fundamentally alter the investment thesis for ResMed. The transactions are standard and do not suggest a change in the company's operational or financial trajectory, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

ResMed, RMD, Michael J. Farrell, CEO, Chairman, SEC Form 4, Insider Trading, Stock Ownership, Restricted Stock Units, RSU Vesting, Executive Compensation, Performance Metrics